Genomics and the development of new diagnostics and anti-Candida drugs

M. Weig, Alistair James Petersen Brown

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Pathogenic Candida species remain a significant medical problem despite the availability of antifungal therapies. Two key issues must be addressed to improve the treatment of life-threatening systemic Candida infections. First, advanced diagnostic tools are required to facilitate the early identification of these infections, when therapeutic intervention is more likely to be effective. Second, improved antifungal therapies are needed. These therapies, which might include combinations of antifungals, need to be less toxic to the patient and more potent in killing a broader range of Candida species. Recent advances in unravelling the genomics of these species should facilitate efforts to achieve these goals. We discuss the contribution of genomics to the development of novel antifungals and new diagnostic tools.
Original languageEnglish
Pages (from-to)310-317
Number of pages8
JournalTrends in Microbiology
Issue number7
Early online date14 Jun 2007
Publication statusPublished - Jul 2007


Dive into the research topics of 'Genomics and the development of new diagnostics and anti-Candida drugs'. Together they form a unique fingerprint.

Cite this